CCIA
DFTX

Campbell & Co Investment Adviser’s Definium Therapeutics DFTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,755
Closed -$468K – 1230
2026
Q1 		$468K Buy
+24,755
New +$420K 0.03% 773

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Campbell & Co Investment Adviser's DFTX Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 24,755 shares — an estimated $468K sold.

Campbell & Co Investment Adviser first reported a position in DFTX in Q1 2026 and held it in 1 quarter. The position peaked at $468K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 24,755 Definium Therapeutics shares in Q2 2026, an estimated $468K.
  • Campbell & Co Investment Adviser first reported a position in Definium Therapeutics in Q1 2026 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Definium Therapeutics position peaked at $468K in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.